EGI
ASND icon

EAM Global Investors’s Ascendis Pharma A/S ASND Stock Holding History

EAM Global Investors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-23,009
Closed -$2.65M – 118
2019
Q2 		$2.65M Sell
23,009
-2,446
-10% -$293K 1.13% 15
2019
Q1 		$3M Buy
+25,455
New +$2.23M 1.33% 14

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

EAM Global Investors's ASND Position: Q3 2019 in Review

EAM Global Investors sold out of Ascendis Pharma A/S (ASND) in Q3 2019, closing a stake of 23,009 shares — an estimated $2.65M sold.

EAM Global Investors first reported a position in ASND in Q1 2019 and held it in 2 quarters. The position peaked at $3M in Q1 2019. 129 funds tracked by Wall St. Rank hold ASND as of Q3 2019.

  • EAM Global Investors reported no remaining Ascendis Pharma A/S position as of Q3 2019 after selling out during the quarter.
  • EAM Global Investors sold 23,009 Ascendis Pharma A/S shares in Q3 2019, an estimated $2.65M.
  • EAM Global Investors first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 2 quarters.
  • EAM Global Investors's Ascendis Pharma A/S position peaked at $3M in Q1 2019.
  • 129 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2019.

Based on EAM Global Investors's 13F filing for Q3 2019, filed 13 Nov 2019.